L. Daniel Browne

All filings by L. Daniel Browne on record concern Revance Therapeutics, Inc. Between 11 February 2014 and 28 June 2019, the trades on record add up to 46 filings.

The open-market side counts 1 purchase for €80k alongside 18 sales for €3.6M. Taken together, the sales exceed the purchases by €3.6M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 14 share grants and 5 option exercises. In 2019 alone, the filings show no purchases and 2 sales.

Most recently, on 2 July 2019, the filings show a transaction worth €9,690 in Revance Therapeutics, Inc. The most recent open-market purchase was published on 1 December 2014, 4,360 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.